Device Firms Eye Rx Markets; Medtronic Moves Toward “Organ Restoration”
Medtronic's long-term strategy is likely to include a much more prominent role in biotechnology, Senior VP-Medicine & Technology Stephen Oesterle told the recent Wharton Health Care Business Conference in Philadelphia
You may also be interested in...
Johnson & Johnson is moving towards a business model focused on offering "product solutions" for the health care system, Biopharmaceuticals Group Chairman Joseph Scodari told the Wharton Health Care Business Conference Feb. 19 in Philadelphia
Pfizer plans to follow the blueprint set by its disease management agreement in Florida to forge "creative" agreements with other public and private payors, CFO David Shedlarz told the J.P. Morgan health care conference in San Francisco Jan. 14
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011